CA3029621A1 - Compositions and methods for treatment of copd - Google Patents

Compositions and methods for treatment of copd Download PDF

Info

Publication number
CA3029621A1
CA3029621A1 CA3029621A CA3029621A CA3029621A1 CA 3029621 A1 CA3029621 A1 CA 3029621A1 CA 3029621 A CA3029621 A CA 3029621A CA 3029621 A CA3029621 A CA 3029621A CA 3029621 A1 CA3029621 A1 CA 3029621A1
Authority
CA
Canada
Prior art keywords
hydroxyacetoxy
phenyl
cyclopentyl
methylpyrrolidinium
carboxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3029621A
Other languages
English (en)
French (fr)
Inventor
Nicholas S. Bodor
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Publication of CA3029621A1 publication Critical patent/CA3029621A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3029621A 2016-07-01 2017-06-30 Compositions and methods for treatment of copd Abandoned CA3029621A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662357730P 2016-07-01 2016-07-01
US201662357711P 2016-07-01 2016-07-01
US62/357,730 2016-07-01
US62/357,711 2016-07-01
PCT/US2017/040348 WO2018006001A1 (en) 2016-07-01 2017-06-30 Compositions and methods for treatment of copd

Publications (1)

Publication Number Publication Date
CA3029621A1 true CA3029621A1 (en) 2018-01-04

Family

ID=60787597

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3029621A Abandoned CA3029621A1 (en) 2016-07-01 2017-06-30 Compositions and methods for treatment of copd

Country Status (5)

Country Link
US (1) US20190224164A1 (https=)
EP (1) EP3478365A4 (https=)
JP (1) JP2019519572A (https=)
CA (1) CA3029621A1 (https=)
WO (1) WO2018006001A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112367859A (zh) * 2018-07-31 2021-02-12 韩国韩医学研究院 包含罗汉果提取物作为有效成分的用于预防、改善或治疗呼吸系统疾病的组合物
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417147B2 (en) * 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
KR102241660B1 (ko) * 2013-03-15 2021-04-19 보도르 라보래토리즈, 인크. 다한증 치료용 항콜린성 글리코피롤레이트 에스테르
JP2017507959A (ja) * 2014-03-13 2017-03-23 ボドール ラボラトリーズ， インコーポレイテッド 選択された抗コリン作動性両性イオンの使用

Also Published As

Publication number Publication date
JP2019519572A (ja) 2019-07-11
EP3478365A1 (en) 2019-05-08
US20190224164A1 (en) 2019-07-25
EP3478365A4 (en) 2020-03-04
WO2018006001A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
US11090294B2 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US6433027B1 (en) Medicament compositions based on tiotropium bromide and formoterol fumarate
EP1957451B1 (en) Soft anticholinergic zwitterions
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
US20100329996A1 (en) Novel Combination of Therapeutic Agents
JP2019038818A (ja) 医薬組成物
CA2496699A1 (en) Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
CN104994854A (zh) 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
JP2014516062A (ja) ウメクリジニウム及びコルチコステロイドを含む組合せ
JP2022520990A (ja) 呼吸器疾患の治療の方法
EP1610787B1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases
US20170202858A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd
EP1948596B1 (en) Soft anticholinergic esters
JP2014518894A (ja) ウメクリジニウムを含む乾燥粉末インヘラー組成物
CA3029621A1 (en) Compositions and methods for treatment of copd
US9795561B2 (en) Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
US20070185067A1 (en) Ciclesonide and glycopyrronium combination
WO2010097114A1 (en) Novel combination of therapeutic agents
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
EP1658063B1 (en) Advantageous combinations for inhalation of nacystelyn and bronchodilators
WO2010008341A1 (en) A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
JP2013056925A (ja) アンドラスト／グルココルチコイドの併用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230928